Friday, July 3, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
DEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets PaidyesterdayENERGYThe Interconnect Loser: Why FERC's Co-Location Ruling Could Squeeze Merchant Nuclear Margins4 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet TailwindyesterdayHEALTHCAREGLP-1 Coverage Mandate: The Federal Obesity Drug Windfall for Lilly and Novo4 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big TechyesterdayENERGYVistra vs. Constellation: Same Nuclear Tax Credit, Very Different Downside if Congress Kills It4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is MovingyesterdayHEALTHCAREFDA Accelerated Approval Reform: The Vertex Model Every Biotech Wants4 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real MoneyyesterdayENERGYTalen Energy: The Merchant Nuclear Stock That Only Washington Can Break4 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending BoomyesterdayHEALTHCAREThe Medicare Drug Negotiation Trade: Who Gets Hurt When Washington Sets the Price4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger MarketyesterdayENERGYBWXT: The Naval Nuclear Contractor Riding a Civilian Policy Wave4 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company ForeveryesterdayENERGYThe NRC Discount Helps Oklo More Than NuScale — Because NuScale Already Paid Full Price4 weeks agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock2 days agoCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers2 days agoENERGYForget Which Reactor Wins — GE Vernova Owns the Queue4 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch2 days agoCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political2 days agoCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending2 days agoENERGYCentrus vs. Cameco: Washington's Russian Uranium Ban Splits the Nuclear Fuel Chain4 weeks agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game2 days agoENERGYThe HALEU Contract Nobody Prices In4 weeks agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk3 days agoCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade3 days agoENERGYWhy Constellation (CEG) Is Really a Policy Stock, Not a Utility Stock4 weeks agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet4 days agoCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners4 weeks agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX4 days agoCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It4 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation4 days agoENERGYWillow Isn't an Oil Play. It's an Interior Department Play.4 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream4 days agoCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade3 weeks agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides5 days agoENERGYWho Gets Exposed When the SPR Refill Never Happens3 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It5 days agoENERGYWashington Fixed the LNG Permit. It Can't Fix a County Courthouse in Guilford County.3 weeks agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine6 days agoENERGYThe Jones Act's Hidden LNG Winner: Foreign Tankers, Not U.S. Shippers, Cash In3 weeks agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order6 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model3 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program6 days agoENERGYHalliburton vs. SLB: Who Actually Cashes In on Methane Compliance3 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes6 days agoENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.3 weeks agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenlylast weekTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oillast weekTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differentlylast weekENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog3 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivotlast weekENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners3 weeks agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Throughlast weekTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock3 weeks agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Storylast weekENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll3 weeks agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguiselast weekTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First3 weeks agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratoslast weekTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Betlast weekDEFENSEThe Refueling Line Nobody Prices Into BWXT3 weeks agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price3 weeks agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast weekENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers3 weeks agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washingtonlast weekTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two3 weeks agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hublast weekDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat2 weeks agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spendinglast weekENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom2 weeks agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Primelast weekDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch2 weeks agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alivelast weekDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes2 weeks agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AIlast weekDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization2 weeks agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus2 weeks agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear2 weeks agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors2 weeks agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch2 weeks agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money2 weeks agoDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop2 weeks agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One2 weeks agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks ago
That's your last free article this week. Create a free account for 2 a week — or go Pro for everything.Go Pro →
Healthcare

The GLP-1 Boom's Toll Booth: Contract Manufacturers Win However the Obesity-Drug Race Ends

Lilly and Novo's capacity crunch, plus a tariff regime that punishes offshore drug manufacturing, is quietly funneling GLP-1 profits to the fill-finish and packaging suppliers behind every brand.

Image: Money Racket
By at Money Racket · Apr 19, 2026

Eli Lilly and Novo Nordisk can't manufacture their way out of the GLP-1 shortage alone, and Washington just made sure they won't have to. Novo Holdings' $16.5 billion buyout of Catalent handed Novo three fill-finish plants; Lilly has publicly farmed out tirzepatide drug-product work to outside CDMOs while it builds its own Indiana, Texas, and Alabama sites. Layer on the White House's April 2026 Section 232 proclamation — a tariff regime that defaults to 100% duties on imported pharmaceuticals and APIs starting July 31, 2026, but forgives companies that sign onshoring agreements — and the incentive is explicit: build sterile injectable capacity in the U.S., or pay for it at the border. Neither Lilly nor Novo can absorb enough of that build-out internally on the timeline Ozempic-and-Zepbound demand demands. That gap gets filled by contract manufacturers, and it doesn't matter whose molecule wins the obesity market — someone still has to fill the pen.

Who cashes in:

  • TMO (Thermo Fisher Scientific) — its Patheon CDMO arm is the industry's largest sterile fill-finish operator; in 2025 it bought Sanofi's Ridgefield, NJ injectable plant specifically to build a North American autoinjector and fill-finish hub, and management told investors at JPMorgan Healthcare in January 2026 it's already booking contracts from customers relocating manufacturing out of Asia and Europe — exactly the onshoring-agreement trade the tariff regime rewards.
  • WST (West Pharmaceutical Services) — makes the elastomer stoppers, seals, plungers, and auto-injector components every GLP-1 pen and vial needs regardless of brand; the company raised full-year 2026 EPS guidance directly citing GLP-1 volume and just opened a 165,000-square-foot expansion in Dublin dedicated to high-volume injectables.
It doesn't matter whose molecule wins the obesity market — someone still has to fill the pen.

Who is exposed:

  • VKTX (Viking Therapeutics) — its entire GLP-1 supply chain, API through fill-finish for both injectable and oral VK2735, runs through CordenPharma, a privately held European CDMO. Viking has no U.S. onshoring position of its own to hide behind and no equity upside from the domestic capacity boom — it's a tariff-and-tariff-negotiation dependent, not a beneficiary, if Commerce ever widens Section 232 scope or renegotiates country-specific terms.
  • LLY and NVO themselves carry a subtler exposure: every dollar spent qualifying and paying outside fill-finish capacity is a dollar of margin the CDMO layer captures instead of the branded manufacturer, even as both companies remain the visible face of GLP-1 earnings risk.

The play: Skip picking the eventual obesity-drug market-share winner and buy the toll booth both winners have to pass through. Watch Commerce's running list of company-specific onshoring agreements and each CDMO's disclosed capital commitments — that's where the actual capacity, and the actual multi-year contracts, get locked in.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →